JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1995; 25:342-348
© 1995 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okumura, K
Right arrow Articles by Tanaka, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okumura, K
Right arrow Articles by Tanaka, H

Effects of brain (B-type) natriuretic peptide on coronary artery diameter and coronary hemodynamic variables in humans: comparison with effects on systemic hemodynamic variables

K Okumura, H Yasue, H Fujii, K Kugiyama, K Matsuyama, M Yoshimura, M Jougasaki, K Kikuta, H Kato, H Tanaka, et al.

Division of Cardiology, Kumamoto University School of Medicine, Japan.

OBJECTIVES. This study attempted to clarify the effects of human brain (B-type) natriuretic peptide on coronary artery diameter and coronary vascular resistance in humans. BACKGROUND. Brain natriuretic peptide induces vasodilation in systemic circulation by activating particulate guanylate cyclase of the vascular smooth muscle. METHODS. In 13 patients with normal coronary arteries and left ventricular function, brain natriuretic peptide was infused at 0.5 microgram/kg body weight per min for 4 min into the left main coronary artery (six patients, Group A) or into the pulmonary artery (seven patients, Group B). Systemic hemodynamic variables and coronary sinus blood flow were measured before and after the infusion. The lumen diameter of the left coronary artery was quantitatively measured. RESULTS. In both groups, brain natriuretic peptide significantly increased heart rate and decreased mean arterial pressure. Rate-pressure product remained unchanged in both groups. Brain natriuretic peptide decreased systemic vascular resistance index significantly in both groups (both p < 0.01 vs. baseline), and there was no difference in the effect between the groups. Brain natriuretic peptide decreased coronary vascular resistance in Group A (p < 0.01 vs. baseline) but did not affect coronary vascular resistance in Group B (p < 0.01 vs. Group A). The lumen diameters of the proximal and distal segments of the left coronary artery were increased significantly after brain natriuretic peptide in both groups. After infusion of brain natriuretic peptide, mean plasma level of brain natriuretic peptide in the coronary sinus increased from 36 to 130,411 pg/ml in Group A and from 64 to 12,329 pg/ml in Group B. CONCLUSIONS. Brain natriuretic peptide shows a vasodilator effect on the coronary artery system in humans. However, the effect does not appear uniformly but is seen preferentially in the epicardial coronary artery. The sensitivity of the coronary resistance vessels to brain natriuretic peptide is low compared with that of the resistance vessels of the systemic circulation.


This article has been cited by other articles:


Home page
ChestHome page
S. de Denus, C. Pharand, and D. R. Williamson
Brain Natriuretic Peptide in the Management of Heart Failure: The Versatile Neurohormone
Chest, February 1, 2004; 125(2): 652 - 668.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. D. Michaels, A. Klein, J. A. Madden, and K. Chatterjee
Effects of Intravenous Nesiritide on Human Coronary Vasomotor Regulation and Myocardial Oxygen Uptake
Circulation, June 3, 2003; 107(21): 2697 - 2701.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
H. Peter Brunner-La Rocca, W. Kiowski, D. Ramsay, and G. Sutsch
Therapeutic benefits of increasing natriuretic peptide levels
Cardiovasc Res, August 15, 2001; 51(3): 510 - 520.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
J. Bonatti, W. Dichtl, A. Lercher, and B. Puschendorf
Natriuretic peptides stimulate cyclic guanosine monophosphate production in human saphenous vein and internal mammary artery
Eur. J. Cardiothorac. Surg., February 1, 2000; 17(2): 175 - 181.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. Zellner, A. A. Protter, E. Ko, M. R. Pothireddy, T. DeMarco, S. J. Hutchison, T. M. Chou, K. Chatterjee, and K. Sudhir
Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries
Am J Physiol Heart Circ Physiol, March 1, 1999; 276(3): H1049 - H1057.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
K. T. Jensen, J. Carstens, and E. B. Pedersen
Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans
Am J Physiol Renal Physiol, January 1, 1998; 274(1): F63 - F72.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. Yamamoto, J. C. Burnett Jr., and M. M. Redfield
Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart
Am J Physiol Heart Circ Physiol, November 1, 1997; 273(5): H2406 - H2414.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1995 by the American College of Cardiology Foundation.